Distal pancreatectomy with celiac axis resection(DP-CAR) for pancreatic cancer: An analysis of 40 cases
10.19538/j.cjps.issn1005-2208.2019.11.18
- Author:
Jing SHEN
1
;
Sui-zhi GAO
1
;
Hong-yun MA
1
Author Information
1. Department of Pancreatic Surgery, Changhai Hospital, Naval Military Medical University Shanghai 200433, China
- Publication Type:Journal Article
- Keywords:
pancreatic cancer;
distal pancreatectomy with celiac axis resection;
pancreatic fistula;
survival
- From:
Chinese Journal of Practical Surgery
2019;39(11):1195-1198
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE: To assess the safety and efficacy of distal pancreatectomy with celiac axis resection(DP-CAR).METHODS: The clinical and pathological data of 40 patients with pancreatic cancer who underwent DP-CAR at the Changhai Hospital affiliated to the Naval Military Medical University from January 2012 to December 2016 were analyzed retrospectively.The postoperative incidence of complications,mortality and overall survival were analyzed respectively.RESULTS: The incidence of complication in the 40 patients(Clavien-Dindo score≥2) was 32.5%(13 cases)including 1 case(2.5%) died of liver failure in 90 days after surgery due to hepatic ischemia,6 cases(15.0%) of grade B or above pancreatic fistula,7 cases(17.5%) of gastric emptying disorder,6 cases(15,0%) of severe abdominal infection,4 cases(10.0%) of chyle leakage,and 4 cases(10%) of postpancreatectomy hemorrhage(PPH).Total median survival was19.1 months(IQR 8.9,30.8 months),one-year,three-year and five-year survival rate:62.5%,17.5% and 5.0%.Patients of T4(median survival:T4 14.2 months vs.T1-3 24.1 months,P=0.0225),lymph node metastasis of N1-2(median survival:N1-2 8.8 months vs.NO 23.2 months,P=0.00967) had a worse median survival time.CONCLUSION: In high-selective patients with pancreatic body/tail cancer,the morbidity,mortality and median survival after DP-CAR surgery are acceptable,and patients with T4 and regional lymph nodes enlargement in preoperative imaging evaluation should be performed neoadjuvant therapy,and then be re-evaluated before DP-CAR.
